Novo Nordisk has launched the first GLP-1 weight-loss tablet approved for use in the UK [1].
The rollout represents a significant shift in obesity treatment by offering a pill alternative to injectable medications. Officials said the UK's growing obesity crisis is a "ticking bomb" [1].
Production of the Wegovy tablets is centered at a Novo Nordisk factory in Copenhagen, Denmark [1]. This facility manufactures the tablets specifically for the UK market to meet anticipated demand. The approval for the tablet form was announced in early June 2026, with availability in pharmacies beginning the following Monday [2, 3].
Demand for the new treatment is already high. Reports indicate that 70,000 Britons are queueing for the Wegovy tablets [4]. The medication is the first of its kind in the GLP-1 class to be approved as a tablet for weight loss in the country [1].
Novo Nordisk executives and the head of Wegovy have overseen the integration of this new delivery method into the healthcare system. The move to a tablet format is intended to increase accessibility for patients who may be averse to needles, or who require a more convenient dosing schedule.
Pharmacy distribution began in mid-June 2026, following the regulatory green light [2, 3]. The company continues to scale production in Copenhagen to ensure the supply chain can handle the volume of patients seeking the drug.
“The UK's growing obesity crisis has been described by officials as a "ticking bomb".”
The transition from injectable GLP-1 agonists to oral tablets removes a significant psychological and physical barrier for patients, likely increasing the total addressable market for weight-loss drugs. By scaling production in Denmark for the UK market, Novo Nordisk is positioning itself to dominate the pharmacological response to the UK's obesity epidemic, though the high demand suggests that supply chain bottlenecks may persist despite the new manufacturing capacity.
